1. Home
  2. HLNE vs TNGX Comparison

HLNE vs TNGX Comparison

Compare HLNE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Lane Incorporated

HLNE

Hamilton Lane Incorporated

N/A

Current Price

$85.97

Market Cap

4.5B

Sector

Finance

ML Signal

N/A

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

N/A

Current Price

$23.66

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HLNE
TNGX
Founded
1991
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.1B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
HLNE
TNGX
Price
$85.97
$23.66
Analyst Decision
Buy
Strong Buy
Analyst Count
8
12
Target Price
★ $129.38
$45.18
AVG Volume (30 Days)
554.5K
★ 2.9M
Earning Date
11-03-2026
11-03-2026
Dividend Yield
★ 2.80%
N/A
EPS Growth
★ 41.64
26.89
EPS
★ 3.98
N/A
Revenue
★ $758,993,000.00
$62,384,000.00
Revenue This Year
$24.96
N/A
Revenue Next Year
$10.58
N/A
P/E Ratio
$21.52
★ N/A
Revenue Growth
6.46
★ 48.29
52 Week Low
$71.88
$6.69
52 Week High
$155.66
$34.39

Technical Indicators

Market Signals
Indicator
HLNE
TNGX
Relative Strength Index (RSI) 39.16 48.85
Support Level $86.48 $19.74
Resistance Level $88.66 $25.93
Average True Range (ATR) 2.93 1.58
MACD 0.24 -0.08
Stochastic Oscillator 50.99 51.64

Price Performance

Historical Comparison
HLNE
TNGX

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: